MK-5108是一种高选择性的Aurora A抑制剂,IC50为0.064 nM,作用于Aurora A比作用于Aurora B/C选择性高220和190倍,抑制TrkA,选择性低100倍。
MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. Phase 1.
0 μM-1 μM
30 mg/kg 口服处理
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Shimomura T, et al. Mol Cancer Ther. 2010, 9(1), 157-166.
[2] Shan W, et al. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma. Clin Cancer Res. 2012 Jun 15;18(12):3352-65.
分子式 C22H21ClFN3O3S |
分子量 461.94 |
CAS号 1010085-13-8 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 90 mg/mL |
Water <1 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT00543387 | Cancer, Neoplasms, Tumors | Drug: MK-5108|Drug: docetaxel | Merck Sharp & Dohme Corp. | Phase 1 | 2008-03-01 | 2016-01-21 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们